The drug Novartis Jakavi looked as blockbuster with positive data
In a trial and successful research the popular Novartis drug Jakavi has achieved its important goal for patients having a rare form of blood cancer, placing it on track to turn out to be a potential blockbuster treatment along with a sales target of $1 billion and more.
As a part of Novartis' the Jakavi with its growth products worked well to achieved sales target in last year to reach a figure of $163 million.
J. Safra Sarasin analyst David Kaegi says "With the additional indication of polycythemia vera now likely to get approved next year, Jakavi definitely emerges as another new drug with blockbuster potential for Novartis. Vontobel analyst Andrew Weiss forecasts peak sales of 500 million Swiss francs ($567 million) for each therapeutic application.”
A positive record for Jakavi has arrived after French participant Sarnoff get forced to stop the progress of all clinical reset and cancel all plans to go for approval of fedratinib.